Engineers Gate Manager LP Cuts Position in IDEXX Laboratories, Inc. (IDXX)

Engineers Gate Manager LP reduced its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 22.3% during the 4th quarter, HoldingsChannel reports. The fund owned 11,511 shares of the company’s stock after selling 3,307 shares during the quarter. Engineers Gate Manager LP’s holdings in IDEXX Laboratories were worth $1,800,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of IDXX. D.A. Davidson & CO. lifted its position in IDEXX Laboratories by 160.4% in the 2nd quarter. D.A. Davidson & CO. now owns 625 shares of the company’s stock valued at $100,000 after acquiring an additional 385 shares in the last quarter. BB&T Investment Services Inc. bought a new stake in IDEXX Laboratories in the 2nd quarter valued at $104,000. Zions Bancorporation bought a new stake in IDEXX Laboratories in the 3rd quarter valued at $162,000. Benjamin F. Edwards & Company Inc. lifted its position in IDEXX Laboratories by 1,000.0% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 1,100 shares of the company’s stock valued at $172,000 after acquiring an additional 1,000 shares in the last quarter. Finally, SignalPoint Asset Management LLC bought a new stake in IDEXX Laboratories in the 4th quarter valued at $200,000. 86.72% of the stock is currently owned by institutional investors and hedge funds.

Shares of IDEXX Laboratories, Inc. (IDXX) opened at $176.83 on Thursday. The company has a debt-to-equity ratio of -11.26, a current ratio of 0.97 and a quick ratio of 0.80. IDEXX Laboratories, Inc. has a 52 week low of $140.63 and a 52 week high of $198.73. The stock has a market cap of $15,703.73, a price-to-earnings ratio of 56.98, a price-to-earnings-growth ratio of 2.21 and a beta of 0.58.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Thursday, February 1st. The company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.04. IDEXX Laboratories had a net margin of 13.36% and a negative return on equity of 432.19%. The firm had revenue of $506.00 million for the quarter, compared to analyst estimates of $490.51 million. During the same period in the previous year, the business earned $0.58 EPS. The company’s revenue was up 14.2% compared to the same quarter last year. equities research analysts anticipate that IDEXX Laboratories, Inc. will post 4.09 earnings per share for the current fiscal year.

In other IDEXX Laboratories news, CEO Jonathan W. Ayers sold 18,000 shares of IDEXX Laboratories stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $148.35, for a total value of $2,670,300.00. Following the sale, the chief executive officer now directly owns 1,064,573 shares in the company, valued at approximately $157,929,404.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Brian P. Mckeon sold 6,602 shares of IDEXX Laboratories stock in a transaction on Monday, February 5th. The shares were sold at an average price of $181.36, for a total transaction of $1,197,338.72. Following the completion of the sale, the vice president now owns 47,040 shares in the company, valued at $8,531,174.40. The disclosure for this sale can be found here. Insiders sold a total of 100,762 shares of company stock worth $16,732,324 over the last quarter. Company insiders own 2.77% of the company’s stock.

Several equities research analysts recently commented on IDXX shares. Zacks Investment Research cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, October 18th. BidaskClub cut shares of IDEXX Laboratories from a “hold” rating to a “sell” rating in a research report on Saturday, December 16th. Bank of America boosted their price objective on shares of IDEXX Laboratories from $200.00 to $220.00 and gave the company a “buy” rating in a research report on Friday, February 2nd. Piper Jaffray Companies boosted their price objective on shares of IDEXX Laboratories to $211.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $185.00 price objective on shares of IDEXX Laboratories in a research report on Tuesday, October 24th. One analyst has rated the stock with a sell rating, five have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $194.00.

COPYRIGHT VIOLATION NOTICE: “Engineers Gate Manager LP Cuts Position in IDEXX Laboratories, Inc. (IDXX)” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://sportsperspectives.com/2018/02/08/engineers-gate-manager-lp-cuts-position-in-idexx-laboratories-inc-idxx.html.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply